ArticleCellular oncology (Dordrecht, Netherlands)2026
BCAA catabolism mediates POU2AF1 propionylation to enhance T-ALL development.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lysine Propionylation as a Metabolically Coupled PTM: Mechanisms, Functional Consequences, and Therapeutic Potentials.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive, life-threatening hematological malignancy with limited therapeutic regimens. While metabolic reprogramming is known to play critical roles in leukemogenesis, how distinct metabolic pathways orchestrate T-ALL pathogenesis remains largely unknown. We herein aim to unravel how the branched-chain amino acid (BCAA) metabolism fine-tunes T-ALL cell fates.
methodsMetabolomic and transcriptomic analyses were performed to identify branched-chain amino acid transaminase 1 (BCAT1)-associated metabolic and molecular alterations. Functional studies in murine T-ALL models were conducted to evaluate the role of BCAT1 in leukemia development, including the assessment of leukemia burden by flow cytometry during T-ALL development. Biochemical and molecular assays were used to assess POU2AF1 propionylation and its downstream signaling. Clinical datasets were analyzed to investigate the clinical relevance of BCAT1 in T-ALL.
resultsWe revealed that BCAT1 could serve as a critical driver to sustain T-ALL initiation and progression. BCAT1 was highly expressed in both murine and human T-ALL cells and was critical for the self-renewal and homing capacities of leukemia cells. Mechanistically, BCAT1-mediated BCAA catabolism promoted the propionylation of transcriptional coactivator POU2AF1, which further enhanced its ability to transactivate SLC7A11 expression to suppress ferroptosis and support the proliferation of T-ALL cells. Moreover, BCAT1 expression levels were strongly correlated with poor prognosis in T-ALL patients. Combined treatment with dietary BCAA restriction and immune checkpoint blockade synergistically inhibited T-ALL progression.
conclusionOur findings reveal a novel mechanism whereby BCAA catabolism mediates ferroptosis resistance through POU2AF1 propionylation during T-ALL progression. Therapeutic blockade of the BCAT1-POU2AF1-SLC7A11 axis holds considerable translational potential in T-ALL treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.